Clinical Trial Detail

NCT ID NCT03903640
Title Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Washington University School of Medicine
Indications

melanoma

Therapies

Ipilimumab + Nivolumab

Age Groups: adult senior

No variant requirements are available.